CRISPR Therapeutics Surges as Gene‑Editing Market Expands: Buy Signal & Strong Investor Interest
CRISPR Therapeutics AG (CRSP) gains investor optimism as the $8.74 billion gene‑transfer market expands, with analysts backing its cutting‑edge gene‑editing pipeline.
3 minutes to read